NCI Awards Contracts to Insight Genetics to Develop NSCLC CDx | GenomeWeb

NEW YORK (GenomeWeb News) – Molecular diagnostics company Insight Genetics said on Monday it has been awarded two SBIR contracts from the National Cancer Institute to develop companion diagnostic tests aimed at lung cancer.

The contracts, which total about $1.7 million, will go toward developing tests to identify and characterize specific genetic mutations in lung cancer patients. The tests would help physicians decide which therapies are best suited for individual patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.